Clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, is a story of contradictions. Its very low tumor mutational burden does not lead to checkpoint inhibitor responses, and its highly immune-infiltrated tumors still produce poor outcomes. So, when researchers at the Francis Crick Institute tested the efficacy of nivolumab, a new drug candidate, they turned to Chromium Single Cell Immune Profiling.
In our new Research Snapshot, you'll find out how the researchers:
